Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 94% confidence The document is titled “분기보고서 (제 27 기) 2026년 01월 01일~2026년 03월 31일” and contains detailed quarterly financial statements, business descriptions, production data, R&D activities, and tables of Q1 results. It is not merely a publication notice or summary but the full interim report filed with Korean regulators. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled '영업(잠정)실적(공정공시)' which translates to 'Operating (Provisional) Results (Fair Disclosure)'. It provides financial performance data for the period 2026-01-01 to 2026-03-31, including sales, operating profit, and net income, with comparisons to previous periods. The document explicitly states that these are provisional results subject to change after audit completion. The length is 2322 characters, which is relatively short but contains substantive financial data, not just an announcement or a certification. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights. It is not a full interim report (IR) because it lacks comprehensive financial statements and detailed analysis, but it is more than a simple announcement. Therefore, the best fit is Earnings Release (ER). Q1 2026
2026-05-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 92% confidence The document is an “임원·주요주주 특정증권등 소유상황보고서” (Schedule 6.1) filed with the Financial Services Commission and Korea Exchange disclosing changes in shareholdings by an officer/major shareholder of Celltrion. It details pre- and post-holding balances, ownership ratios, and specific transactions (e.g., stock dividends). This matches the definition of a director’s/officer’s insider trading or shareholding report, i.e., Director’s Dealing (DIRS). It is not an announcement of a report but the actual regulatory filing itself.
2026-04-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is the official “주식등의 대량보유상황보고서(일반)” (Large Shareholding Status Report), detailing changes in shareholding by (주)셀트리온제약 and its related parties, including precise share counts, ratios, and related transaction details. This matches a Major Shareholding Notification as it reports threshold crossings and detailed ownership positions. It is not an announcement of a report publication but the full disclosure itself.
2026-04-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 94% confidence The document is a Korean ‘임원ㆍ주요주주 특정증권등 소유상황보고서’, disclosing an officer’s and major shareholder’s holdings and changes in specific securities. This is an insider share transaction and ownership report, matching the Director’s Dealing category.
2026-04-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a Korean insider ownership report (“임원ㆍ주요주주 특정증권등 소유상황보고서”) disclosing securities holdings and changes by an executive (유영호) of Celltrion Pharm. This matches the definition of a Director’s Dealing report (insider share transactions).
2026-04-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.